Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT06136624 (OMAHA-003) für Metastasierender Prostatakrebs ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche
MerckStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003) Phase 3 1.310 Randomisiert Offene Studie Gesamtüberleben
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06136624 (OMAHA-003) untersucht Behandlung im Zusammenhang mit Metastasierender Prostatakrebs. Diese interventionsstudie der Phase 3 hat den Status offene rekrutierung und startete am 31. Dezember 2023. Es ist geplant, 1.310 Teilnehmer aufzunehmen. Durchgeführt von Merck wird der Abschluss für 2. August 2028 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 20. März 2026 aktualisiert.
Kurzbeschreibung
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to...Mehr anzeigen
Offizieller Titel
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
Erkrankungen
Metastasierender ProstatakrebsPublikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:Weitere Studien-IDs
- OMAHA-003
- 5684-003
- 2023-504899-25-00 (Andere Kennung) (EU CT)
- MK-5684-003 (Andere Kennung) (MSD)
- jRCT2031240029 (Registerkennung) (Japan Registry of Clinical Trials (jRCT))
- U1111-1287-5304 (Registerkennung) (UTN)
NCT-Nummer
Studienbeginn (tatsächlich)
2023-12-31
Zuletzt aktualisiert
2026-03-20
Studienende (vorauss.)
2028-08-02
Geplante Rekrutierung
1.310
Studientyp
Interventionsstudie
PHASE
Phase 3
Status
Offene Rekrutierung
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellOpevesostat Participants receive opevesostat 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) dose will also be provided to participants for use as rescue medication. | Opevesostat Administered orally Hydrocortisone Administered orally or IM as a rescue medication Fludrocortisone acetate Administered orally Dexamethasone Administered orally as rescue medication |
Aktives VergleichspräparatAbiraterone Acetate or Enzalutamide Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets. | Abirateronacetat Administered orally Enzalutamide Administered orally Prednisone Administered orally |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants | OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~54 months |
OS in AR LBD Mutation-Negative Participants | OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-negative participants will be reported for each study arm. | Up to ~54 months |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review in AR LBD Mutation-Positive Participants | rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~36 months |
rPFS Per Prostate Cancer Working Group-modifiedRECIST 1.1 as Assessed by Blinded Independent Central Review in AR LBD Mutation-Negative Participants | rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~36 months |
Time to Initiation of the First Subsequent Anti-Cancer Therapy or Death (TFST) | TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. | Up to ~54 months |
Objective Response (OR) | OR is determined by PCWG-modified RECIST 1.1 as assessed by BICR. | Up to ~54 months |
Duration of Response (DOR) | DOR is determined by PCWG-modified RECIST 1.1 as assessed by BICR. | Up to ~54 months |
Time to Pain Progression (TTPP) | TTPP is assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and opiate analgesic use (Analgesic Quantification Algorithm \[AQA\] Score). | Up to ~54 months |
Time to Prostate-specific Antigen (PSA) Progression | The time from randomization to PSA progression. The PSA progression date is defined as the date of either: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. | Up to ~54 months |
Time to First Symptomatic Skeletal-related Event (SSRE) | The time from randomization to the first occurrence of any of the following symptomatic skeletal-related events: 1) Use of EBRT to prevent or relieve skeletal symptoms; 2) new symptomatic pathologic bone fracture (vertebral or nonvertebral); 3) spinal cord compression; or 4) tumor-related orthopedic surgical intervention. | Up to ~54 months |
Number of Participants Who Experience an Adverse Event | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~54 months |
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~54 months |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Zugelassene Geschlechter
Alle
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
- Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
- Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
- Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
- Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<1.7 nM)
- Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
- Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
- Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment
- Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment
- If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression >4 weeks since the last flutamide treatment and >6 weeks since the last bicalutamide or nilutamide treatment
- Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization
- Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening.
- Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom
- Has a gastrointestinal disorder that might affect absorption
- Has a history of pituitary dysfunction
- Has poorly controlled diabetes mellitus
- Has clinically significant abnormal serum potassium or sodium level
- Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
- Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization
- Has a history of clinically significant ventricular arrhythmias
- Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization
- Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications
- Participants who have not adequately recovered from major surgery or have ongoing surgical complications
- Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization
- Has received radium-223 or lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or lutetium-177 administered more than 4 weeks before the date of randomization
- Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization
- Has received colony-stimulating factors within 28 days before the date of randomization
- Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and platelet transfusions are acceptable if not given within 28 days of the date of randomization
- Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks
- Has a "superscan" bone scan
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has an active infection requiring systemic therapy
- Has concurrent active HBV or known active HCV infection
- Has a history of long QTc syndrome
- Has any of the following at Screening Visit: hypotension (systolic BP <110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy)
- Is unable to swallow capsules/tablets
- Is currently being treated with cytochrome 450-inducing antiepileptic drugs for seizures
- Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
- Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Systemic use of the following medications within 2 weeks before the first dose of study intervention: strong CYP3A4 inducers (eg, avasimibe, carbamazepine, lumacaftor, phenobarbital, rifampicin, rifapentine, or St John's Wort); P-gp inhibitors (eg, erythromycin, clarithromycin, rifampicin, ketoconazole, itraconazole, posaconazole, artesunate-pyronaridine, ritonavir, indinavir, nelfinavir, atazanavir, glecaprevir-pibrentasvir, simeprevir, ledipasvir-sofosbuvir, verapamil, diltiazem, dronedarone, propafenone, quinidine, cyclosporine, valspodar, or milk thistle \[Silybum marianum\])
- Use of aldosterone antagonist (eg, spironolactone, eplerenone) and phenytoin within 4 weeks before the start of the study intervention
Orion Corporation9 aktive klinische Studien zum ErkundenZentrale Studienkontakte
Kontakt: Toll Free Number, 1-888-577-8839, [email protected]
281 Studienstandorte in 36 Ländern
Bavaria
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696), Munich, Bavaria, 81675, Germany
Aktiv, nicht rekrutierend
Mecklenburg-Vorpommern
HELIOS Kliniken Schwerin ( Site 0694), Schwerin, Mecklenburg-Vorpommern, 19055, Germany
Study Coordinator, Kontakt, +493855202120
Offene Rekrutierung
North Rhine-Westphalia
Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680), Bonn, North Rhine-Westphalia, 53127, Germany
Study Coordinator, Kontakt, +4922828714249
Offene Rekrutierung
Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678), Münster, North Rhine-Westphalia, 48149, Germany
Study Coordinator, Kontakt, 0049251-8344658
Offene Rekrutierung
Schleswig-Holstein
Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691), Lübeck, Schleswig-Holstein, 23538, Germany
Study Coordinator, Kontakt, +4945150043699
Offene Rekrutierung
Thuringia
Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682), Jena, Thuringia, 07747, Germany
Study Coordinator, Kontakt, +49 3641 9 32 9947
Offene Rekrutierung
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679), Berlin, 10117, Germany
Study Coordinator, Kontakt, 0049 30 450615297
Offene Rekrutierung
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705), Hamburg, 20246, Germany
Study Coordinator, Kontakt, +4915222815585
Offene Rekrutierung
Styria
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280), Graz, Styria, 8036, Austria
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Upper Austria
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276), Linz, Upper Austria, 4020, Austria
Study Coordinator, Kontakt, +4373276774724
Offene Rekrutierung
Klinikum Wels-Grieskirchen GmbH ( Site 0279), Wels, Upper Austria, 4600, Austria
Study Coordinator, Kontakt, +4372424152328
Offene Rekrutierung
California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California, 92868, United States
Aktiv, nicht rekrutierend
Stanford Cancer Center ( Site 0036), Palo Alto, California, 94304, United States
Study Coordinator, Kontakt, 650-725-2078
Offene Rekrutierung
Kaiser Permanente Riverside Medical Center ( Site 0099), Riverside, California, 92505, United States
Study Coordinator, Kontakt, 951-809-8361
Offene Rekrutierung
Colorado
Anschutz Cancer Pavilion ( Site 0046), Aurora, Colorado, 80045, United States
Study Coordinator, Kontakt, 302-290-3598
Offene Rekrutierung
University of Colorado Health - Highlands Ranch Hospital ( Site 0111), Highlands Ranch, Colorado, 80129, United States
Study Coordinator, Kontakt, 302-290-3598
Offene Rekrutierung
Colorado Clinical Research ( Site 0067), Lakewood, Colorado, 80228, United States
Aktiv, nicht rekrutierend
University of Colorado Health - Lone Tree Medical Center ( Site 0112), Lone Tree, Colorado, 80124, United States
Study Coordinator, Kontakt, 720-848-5146
Offene Rekrutierung
Connecticut
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven, Connecticut, 06510, United States
Study Coordinator, Kontakt, 203-737-8076
Offene Rekrutierung
Florida
Florida Cancer Specialists - South ( Site 7003), Fort Myers, Florida, 33901, United States
Study Coordinator, Kontakt, 727-364-9201
Offene Rekrutierung
Bruce W. Carter Veterans Affairs Medical Center ( Site 0082), Miami, Florida, 33125, United States
Aktiv, nicht rekrutierend
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051), Miami, Florida, 33136, United States
Study Coordinator, Kontakt, 305-243-1543
Offene Rekrutierung
Illinois
University of Illinois at Chicago ( Site 0105), Chicago, Illinois, 60612, United States
Study Coordinator, Kontakt, 973-330-2391
Offene Rekrutierung
University of Chicago Medical Center ( Site 0045), Chicago, Illinois, 60637, United States
Study Coordinator, Kontakt, 773-702-7609
Offene Rekrutierung
Iowa
University of Iowa ( Site 0047), Iowa City, Iowa, 52242, United States
Study Coordinator, Kontakt, 319-353-8155
Offene Rekrutierung
Kentucky
University of Kentucky Chandler Medical Center ( Site 0048), Lexington, Kentucky, 40536, United States
Aktiv, nicht rekrutierend
Louisiana
Ochsner Clinic Foundation ( Site 0108), New Orleans, Louisiana, 70121, United States
Aktiv, nicht rekrutierend
Maryland
Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore, Maryland, 21201, United States
Study Coordinator, Kontakt, 410-707-4011
Offene Rekrutierung
Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore, Maryland, 21201, United States
Study Coordinator, Kontakt, 410-707-4011
Offene Rekrutierung
Michigan
Henry Ford Hospital ( Site 0015), Detroit, Michigan, 48202, United States
Aktiv, nicht rekrutierend
Minnesota
M Health Fairview Clinics and Surgery Center ( Site 0019), Minneapolis, Minnesota, 55455, United States
Study Coordinator, Kontakt, 612-626-1422
Offene Rekrutierung
Metro-Minnesota Community Clinical Oncology ( Site 0014), Saint Louis Park, Minnesota, 55416, United States
Study Coordinator, Kontakt, 952-993-3252
Offene Rekrutierung
Missouri
Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062), St Louis, Missouri, 63110, United States
Aktiv, nicht rekrutierend
Nebraska
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095), Omaha, Nebraska, 68105, United States
Study Coordinator, Kontakt, 402-559-8500
Offene Rekrutierung
Nevada
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada, 89148, United States
Study Coordinator, Kontakt, 702-952-1251
Offene Rekrutierung
New Jersey
Atlantic Health System Morristown Medical Center ( Site 0115), Morristown, New Jersey, 07960, United States
Study Coordinator, Kontakt, 973-971-7960
Offene Rekrutierung
Rutgers Cancer Institute of New Jersey ( Site 0033), New Brunswick, New Jersey, 08901, United States
Aktiv, nicht rekrutierend
New York
James J. Peters VA Medical Center ( Site 0088), The Bronx, New York, 10468, United States
Study Coordinator, Kontakt, 718-584-9000
Offene Rekrutierung
Ohio
University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio, 44106, United States
Study Coordinator, Kontakt, 216-844-3951
Offene Rekrutierung
Oregon
Oregon Health and Science University ( Site 0028), Portland, Oregon, 97239, United States
Aktiv, nicht rekrutierend
VA Portland Health Care System ( Site 0058), Portland, Oregon, 97239, United States
Study Coordinator, Kontakt, 503-220-8262
Offene Rekrutierung
Pennsylvania
AHN Allegheny General Hospital ( Site 0001), Pittsburgh, Pennsylvania, 15212, United States
Aktiv, nicht rekrutierend
South Carolina
Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083), Charleston, South Carolina, 29401, United States
Aktiv, nicht rekrutierend
South Dakota
Avera Cancer Institute - Pierre ( Site 0118), Pierre, South Dakota, 57501, United States
Study Coordinator, Kontakt, 605-224-3370
Offene Rekrutierung
Avera Cancer Institute- Research ( Site 0094), Sioux Falls, South Dakota, 57105, United States
Study Coordinator, Kontakt, 605-322-6900
Offene Rekrutierung
Avera Cancer Institute - Yankton ( Site 0117), Yankton, South Dakota, 57078, United States
Study Coordinator, Kontakt, 605-655-1800
Offene Rekrutierung
Tennessee
SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, 37203, United States
Study Coordinator, Kontakt, 615-218-4647
Offene Rekrutierung
Texas
Texas Oncology - Central/South Texas ( Site 8003), Austin, Texas, 78731, United States
Study Coordinator, Kontakt, 512-427-9400
Offene Rekrutierung
Texas Oncology - DFW ( Site 8001), Dallas, Texas, 75246, United States
Aktiv, nicht rekrutierend
Texas Oncology - Gulf Coast ( Site 8002), The Woodlands, Texas, 77380, United States
Study Coordinator, Kontakt, 713-467-1722
Offene Rekrutierung
Virginia
University of Virginia Health System ( Site 0054), Charlottesville, Virginia, 22908, United States
Study Coordinator, Kontakt, 434-327-3029
Offene Rekrutierung
VCU Health Adult Outpatient Pavillion ( Site 0061), Richmond, Virginia, 23219, United States
Aktiv, nicht rekrutierend
Blue Ridge Cancer Care ( Site 0004), Roanoke, Virginia, 24014, United States
Study Coordinator, Kontakt, 540-982-0237
Offene Rekrutierung
Washington
Fred Hutchinson Cancer Center ( Site 0013), Seattle, Washington, 98109, United States
Study Coordinator, Kontakt, 617-413-9079
Offene Rekrutierung
Wisconsin
MEDICAL COLLEGE OF WISCONSIN ( Site 0020), Milwaukee, Wisconsin, 53226, United States
Study Coordinator, Kontakt, 414-805-4600
Offene Rekrutierung
Buenos Aires
Hospital Británico de Buenos Aires-Oncology ( Site 0202), Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina
Study Coordinator, Kontakt, 1143096839
Offene Rekrutierung
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires, B7600FZO, Argentina
Study Coordinator, Kontakt, 02234963224
Offene Rekrutierung
Buenos Aires F.D.
Instituto Alexander Fleming-Alexander Fleming ( Site 0206), Buenos Aires, Buenos Aires F.D., 1426ANZ, Argentina
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205), Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Santa Fe Province
Sanatorio Parque ( Site 0208), Rosario, Santa Fe Province, S2000DVC, Argentina
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Hospital Aleman-Oncology ( Site 0207), Buenos Aires, C1118AAT, Argentina
Study Coordinator, Kontakt, 01148277000
Offene Rekrutierung
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204), Mendoza, M5500AYB, Argentina
Aktiv, nicht rekrutierend
New South Wales
Dubbo Hospital ( Site 0235), Dubbo, New South Wales, 2830, Australia
Study Coordinator, Kontakt, 0268096200
Offene Rekrutierung
Macquarie University-MQ Health Clinical Trials Unit ( Site 0234), Macquarie University, New South Wales, 2109, Australia
Study Coordinator, Kontakt, 0298122979
Offene Rekrutierung
Westmead Hospital ( Site 0232), Westmead, New South Wales, 2145, Australia
Aktiv, nicht rekrutierend
Queensland
Princess Alexandra Hospital-Cancer Care Serices ( Site 0237), Brisbane, Queensland, 4102, Australia
Study Coordinator, Kontakt, +6173176 9289
Offene Rekrutierung
Victoria
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230), Melbourne, Victoria, 3000, Australia
Aktiv, nicht rekrutierend
Espírito Santo
Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320), Vitória, Espírito Santo, 29041-295, Brazil
Aktiv, nicht rekrutierend
Estado de Bahia
Obras Sociais Irma Dulce ( Site 0302), Salvador, Estado de Bahia, 40415-006, Brazil
Aktiv, nicht rekrutierend
Minas Gerais
Hospital Felicio Rocho ( Site 0317), Belo Horizonte, Minas Gerais, 30110-934, Brazil
Aktiv, nicht rekrutierend
Hospital Mario Penna ( Site 0309), Belo Horizonte, Minas Gerais, 30380-472, Brazil
Aktiv, nicht rekrutierend
Paraná
Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314), Curitiba, Paraná, 80440-220, Brazil
Aktiv, nicht rekrutierend
Santa Catarina
Clínica de Neoplasias Litoral ( Site 0305), Itajaí, Santa Catarina, 88301-220, Brazil
Study Coordinator, Kontakt, +5547984046243
Offene Rekrutierung
São Paulo
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308), Bragança Paulista, São Paulo, 12916-542, Brazil
Aktiv, nicht rekrutierend
A. C. Camargo Cancer Center ( Site 0310), São Paulo, São Paulo, 01509-010, Brazil
Aktiv, nicht rekrutierend
Alberta
Cross Cancer Institute ( Site 0332), Edmonton, Alberta, T6G 1Z2, Canada
Study Coordinator, Kontakt, 7804328762
Offene Rekrutierung
Ontario
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336), Ottawa, Ontario, K1H 8L6, Canada
Study Coordinator, Kontakt, 613-737-7700
Offene Rekrutierung
Sunnybrook Research Institute ( Site 0331), Toronto, Ontario, M4N 3M5, Canada
Study Coordinator, Kontakt, 647-533-1023
Offene Rekrutierung
Princess Margaret Cancer Centre ( Site 0330), Toronto, Ontario, M5G 2M9, Canada
Study Coordinator, Kontakt, (416) 946-4501
Offene Rekrutierung
Quebec
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328), Greenfield Park, Quebec, J4V 2H1, Canada
Study Coordinator, Kontakt, 4504665000 ext 3226
Offene Rekrutierung
Centre Hospitalier de l'Université de Montréal ( Site 0326), Montreal, Quebec, H2X 3E4, Canada
Aktiv, nicht rekrutierend
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327), Québec, Quebec, G1J 1Z4, Canada
Study Coordinator, Kontakt, 418 525-4444
Offene Rekrutierung
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329), Sherbrooke, Quebec, J1H 5H4, Canada
Aktiv, nicht rekrutierend
Coquimbo Region
IC La Serena Research ( Site 0356), La Serena, Coquimbo Region, 1720430, Chile
Aktiv, nicht rekrutierend
Los Ríos Region
Clinical Research Chile SpA ( Site 0358), Valdivia, Los Ríos Region, 5110683, Chile
Aktiv, nicht rekrutierend
Maule Region
Clinica Universidad Catolica del Maule-Oncology ( Site 0355), Talca, Maule Region, 3465584, Chile
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Region M. de Santiago
FALP ( Site 0353), Santiago, Region M. de Santiago, 7500921, Chile
Aktiv, nicht rekrutierend
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354), Santiago, Region M. de Santiago, 8330024, Chile
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Bradfordhill-Clinical Area ( Site 0351), Santiago, Region M. de Santiago, 8420383, Chile
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Bradford Hill Norte ( Site 0357), Antofagasta, 1240000, Chile
Aktiv, nicht rekrutierend
Anhui
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408), Hefei, Anhui, 230000, China
Study Coordinator, Kontakt, +86 02782201756
Offene Rekrutierung
Beijing Municipality
Peking University First Hospital-Urology ( Site 0390), Beijing, Beijing Municipality, 100034, China
Study Coordinator, Kontakt, +86 (010) 64008229
Offene Rekrutierung
Beijing Friendship Hospital Affiliate of Capital University ( Site 0396), Beijing, Beijing Municipality, 100050, China
Study Coordinator, Kontakt, +86(010)63138375
Offene Rekrutierung
Beijing Cancer hospital-Urinary Surgery ( Site 0395), Beijing, Beijing Municipality, 100142, China
Study Coordinator, Kontakt, 86 010 8812 1122
Offene Rekrutierung
Chongqing Municipality
The First Affiliated Hospital of Chongqing Medical University ( Site 0427), Chongqing, Chongqing Municipality, 400010, China
Study Coordinator, Kontakt, 023 89012012
Offene Rekrutierung
Chongqing University Cancer Hospital ( Site 0416), Chongqing, Chongqing Municipality, 400030, China
Study Coordinator, Kontakt, 02365075629
Offene Rekrutierung
Southwest Hospital of Third Military Medical University ( Site 0420), Chongqing, Chongqing Municipality, 400038, China
Study Coordinator, Kontakt, 023 68765878
Offene Rekrutierung
Chongqing Three Gorges Central Hospital's ( Site 0426), Chongqing, Chongqing Municipality, 404100, China
Study Coordinator, Kontakt, 023 58103150
Offene Rekrutierung
Fujian
The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414), Fuzhou, Fujian, 350005, China
Study Coordinator, Kontakt, +86059187983333
Offene Rekrutierung
The First Affiliated hospital of Xiamen University-Urology ( Site 0415), Xiamen, Fujian, 361003, China
Study Coordinator, Kontakt, 0592-2132222
Offene Rekrutierung
Guangdong
The First Affiliated Hospital of Guangzhou Medical University ( Site 0412), Guangzhou, Guangdong, 510120, China
Study Coordinator, Kontakt, (020) 83062114
Offene Rekrutierung
Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413), Guangzhou, Guangdong, 511400, China
Study Coordinator, Kontakt, +8602087343533
Offene Rekrutierung
Hubei
Tongji Hospital Tongji Medical,Science & Technology ( Site 0407), Wuhan, Hubei, 430000, China
Study Coordinator, Kontakt, 027-83665555
Offene Rekrutierung
Hubei Cancer Hospital-Urinary surgery ( Site 0406), Wuhan, Hubei, 430079, China
Study Coordinator, Kontakt, 8613907110640
Offene Rekrutierung
Hunan
Hunan Cancer Hospital ( Site 0405), Changsha, Hunan, 410013, China
Study Coordinator, Kontakt, 073189762270
Offene Rekrutierung
Jiangsu
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436), Huaian, Jiangsu, 223300, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377), Nanjing, Jiangsu, 210008, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Affiliated hospital of Jiangnan university ( Site 0434), Wuxi, Jiangsu, 214122, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Jiangxi
Jiangxi Cancer Hospital ( Site 0386), Nanchang, Jiangxi, 330029, China
Study Coordinator, Kontakt, 86079188317256
Offene Rekrutierung
Shaanxi
The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394), Xi'an, Shaanxi, 710004, China
Study Coordinator, Kontakt, 029-87679000
Offene Rekrutierung
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393), Xi'an, Shaanxi, 710061, China
Study Coordinator, Kontakt, 029-85323112
Offene Rekrutierung
Shandong
Yantai Yuhuangding Hospital ( Site 0397), Yantai, Shandong, 264099, China
Study Coordinator, Kontakt, 86 0535 6691999
Offene Rekrutierung
Shangai
Zhongshan Hospital of Fudan University (0430), Shanghai, Shangai, 200032, China
Jianming Guo, Kontakt, 13681971306, [email protected]
Offene Rekrutierung
Shanghai Municipality
Fudan University Shanghai Cancer Center-Urology department ( Site 0376), Shanghai, Shanghai Municipality, 200000, China
Study Coordinator, Kontakt, 021-38196379
Offene Rekrutierung
Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388), Shanghai, Shanghai Municipality, 200041, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Sichuan
The Third People's Hospital of Chengdu (CDTPH) ( Site 0428), Chengdu, Sichuan, 500643, China
Study Coordinator, Kontakt, 67566947
Offene Rekrutierung
West China Hospital, Sichuan University-Urology Surgery ( Site 0417), Chengdu, Sichuan, 610041, China
Study Coordinator, Kontakt, +86028-85422114
Offene Rekrutierung
Nanchong Central Hospital-urology ( Site 0422), Nanchong, Sichuan, 500643, China
Study Coordinator, Kontakt, 08172606822
Offene Rekrutierung
Suining Central Hospital ( Site 0437), Suining, Sichuan, 629000, China
Study Coordinator, Kontakt, 08252292093
Offene Rekrutierung
Tianjin Municipality
Tianjin Medical University Cancer Institute & Hospital ( Site 0392), Tianjin, Tianjin Municipality, 300060, China
Study Coordinator, Kontakt, +862223340123
Offene Rekrutierung
The Second Hospital of Tianjin Medical University ( Site 0391), Tianjin, Tianjin Municipality, 300211, China
Study Coordinator, Kontakt, +8602288326748
Offene Rekrutierung
Xinjiang
Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419), Ürümqi, Xinjiang, 830000, China
Study Coordinator, Kontakt, 86 09917819156
Offene Rekrutierung
Yunnan
The Second Affiliated Hospital Of Kunming Medical University ( Site 0429), Kunming, Yunnan, 650033, China
Study Coordinator, Kontakt, 087165351281
Offene Rekrutierung
Yunnan Province Cancer Hospital ( Site 0418), Kunming, Yunnan, 650107, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Zhejiang
Zhejiang Provincial People's Hospital-Urology ( Site 0378), Hangzhou, Zhejiang, 310014, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Zhejiang Cancer Hospital ( Site 0435), Hangzhou, Zhejiang, 310022, China
Study Coordinator, Kontakt, 0571-88122261
Offene Rekrutierung
The First Hospital of Jiaxing-urology ( Site 0380), Jiaxing, Zhejiang, 314001, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
The First Affiliated Hospital of Ningbo University ( Site 0383), Ningbo, Zhejiang, 315010, China
Study Coordinator, Kontakt, 86057487085588
Offene Rekrutierung
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379), Wenzhou, Zhejiang, 325000, China
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Bogota D.C.
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501), Bogotá, Bogota D.C., 111321, Colombia
Aktiv, nicht rekrutierend
Cesar Department
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502), Valledupar, Cesar Department, 200001, Colombia
Aktiv, nicht rekrutierend
Departamento de Córdoba
IMAT S.A.S ( Site 0504), Montería, Departamento de Córdoba, 230002, Colombia
Aktiv, nicht rekrutierend
Santander Department
Fundación Cardiovascular de Colombia ( Site 0503), Piedecuesta, Santander Department, 681017, Colombia
Aktiv, nicht rekrutierend
Valle del Cauca Department
Fundación Valle del Lili ( Site 0505), Cali, Valle del Cauca Department, 760032, Colombia
Aktiv, nicht rekrutierend
Clínica Imbanaco S.A.S ( Site 0509), Cali, Valle del Cauca Department, 760042, Colombia
Aktiv, nicht rekrutierend
Brno-mesto
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553), Brno, Brno-mesto, 656 53, Czechia
Study Coordinator, Kontakt, +420 543 136 216
Offene Rekrutierung
Moravskoslezský kraj
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554), Ostrava, Moravskoslezský kraj, 708 52, Czechia
Study Coordinator, Kontakt, +420597372264
Offene Rekrutierung
Olomoucký kraj
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555), Olomouc, Olomoucký kraj, 779 00, Czechia
Study Coordinator, Kontakt, +420 588 444 699
Offene Rekrutierung
Praha 5
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551), Prague, Praha 5, 150 06, Czechia
Aktiv, nicht rekrutierend
Capital Region
Rigshospitalet ( Site 0576), Copenhagen, Capital Region, 2100, Denmark
Study Coordinator, Kontakt, +45 35453545
Offene Rekrutierung
Region Syddanmark
Odense Universitetshospital-Department of oncology ( Site 0579), Odense, Region Syddanmark, 5000, Denmark
Aktiv, nicht rekrutierend
Vejle Sygehus ( Site 0578), Vejle, Region Syddanmark, 7100, Denmark
Study Coordinator, Kontakt, +45 79405000
Offene Rekrutierung
Northern Savonia
Kuopion Yliopistollinen Sairaala ( Site 0603), Kuopio, Northern Savonia, 70210, Finland
Study Coordinator, Kontakt, 35817173311
Offene Rekrutierung
Pirkanmaa
Tampereen yliopistollinen sairaala ( Site 0604), Tampere, Pirkanmaa, 33520, Finland
Study Coordinator, Kontakt, 358331166811
Offene Rekrutierung
Southwest Finland
Turku University Hospital-Department of Oncology ( Site 0601), Turku, Southwest Finland, 20520, Finland
Study Coordinator, Kontakt, 35823130729
Offene Rekrutierung
Alsace
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0627), Strasbourg, Alsace, 67200, France
Study Coordinator, Kontakt, +33368767207
Offene Rekrutierung
Gard
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630), Nîmes, Gard, 30029, France
Aktiv, nicht rekrutierend
Ille-et-Vilaine
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632), Rennes, Ille-et-Vilaine, 35042, France
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Puy-de-Dome
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629), Clermont-Ferrand, Puy-de-Dome, 63003, France
Study Coordinator, Kontakt, +33473278005
Offene Rekrutierung
Pyrenees-Atlantiques
Centre Hospitalier de la Côte Basque ( Site 0633), Bayonne, Pyrenees-Atlantiques, 64109, France
Study Coordinator, Kontakt, 33559443535
Offene Rekrutierung
Val-de-Marne
Gustave Roussy ( Site 0626), Villejuif, Val-de-Marne, 94800, France
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Hôpital Européen Georges Pompidou ( Site 0628), Paris, 75015, France
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Queen Mary Hospital ( Site 0727), Hong Kong, Hong Kong
Study Coordinator, Kontakt, +85222553838
Offene Rekrutierung
Prince of Wales Hospital ( Site 0730), Shatin, Hong Kong
Study Coordinator, Kontakt, +85235052211
Offene Rekrutierung
Bács-Kiskun county
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752), Kecskemét, Bács-Kiskun county, 6000, Hungary
Study Coordinator, Kontakt, +3676516719
Offene Rekrutierung
Nógrád megye
Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761), Salgótarján, Nógrád megye, 3100, Hungary
Study Coordinator, Kontakt, +3632522000
Offene Rekrutierung
Pest County
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756), Budapest, Pest County, 1122, Hungary
Study Coordinator, Kontakt, +36122486001171
Offene Rekrutierung
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758), Debrecen, 4032, Hungary
Study Coordinator, Kontakt, +3652411717
Offene Rekrutierung
Dublin
St. Vincent's University Hospital ( Site 0802), Dublin, Dublin, D04 T6F4, Ireland
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Tallaght University Hospital ( Site 0801), Dublin, D24 NR0A, Ireland
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Emek Medical Center ( Site 0830), Afula, 1834111, Israel
Study Coordinator, Kontakt, 0546708579
Offene Rekrutierung
Rambam Health Care Campus-Oncology Division ( Site 0826), Haifa, 3109601, Israel
Study Coordinator, Kontakt, 04-7776234
Offene Rekrutierung
Hadassah Medical Center ( Site 0833), Jerusalem, 9112001, Israel
Study Coordinator, Kontakt, 02-6777111
Offene Rekrutierung
Meir Medical Center. ( Site 0832), Kfar Saba, 4428164, Israel
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Rabin Medical Center ( Site 0828), Petah Tikva, 4941492, Israel
Study Coordinator, Kontakt, 972-50-3745684
Offene Rekrutierung
Sheba Medical Center ( Site 0827), Ramat Gan, 5265601, Israel
Study Coordinator, Kontakt, : +972-35302191
Offene Rekrutierung
Emilia-Romagna
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879), Meldola, Emilia-Romagna, 47014, Italy
Study Coordinator, Kontakt, +390543739100
Offene Rekrutierung
Lombardy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877), Milan, Lombardy, 20133, Italy
Study Coordinator, Kontakt, 00390223903033
Offene Rekrutierung
Ospedale San Raffaele-Oncologia Medica ( Site 0876), Milan, 20132, Italy
Study Coordinator, Kontakt, +390226435668
Offene Rekrutierung
Chiba
Toho University Sakura Medical Center ( Site 0906), Sakura, Chiba, 285-8741, Japan
Study Coordinator, Kontakt, +81434628811
Offene Rekrutierung
Ehime
Ehime University Hospital ( Site 0918), Tōon, Ehime, 791-0295, Japan
Study Coordinator, Kontakt, +81-89-964-5111
Offene Rekrutierung
Fukuoka
Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921), Kitakyushu, Fukuoka, 807-8556, Japan
Aktiv, nicht rekrutierend
Kurume University Hospital ( Site 0920), Kurume, Fukuoka, 830-0011, Japan
Study Coordinator, Kontakt, +81-942-35-3311
Offene Rekrutierung
Hokkaido
Asahikawa Medical University Hospital ( Site 0901), Asahikawa, Hokkaido, 078-8510, Japan
Study Coordinator, Kontakt, +81-166-65-2111
Offene Rekrutierung
Sapporo Medical University Hospital ( Site 0902), Sapporo, Hokkaido, 060-8543, Japan
Study Coordinator, Kontakt, +81-11-611-2111
Offene Rekrutierung
Hokkaido University Hospital ( Site 0931), Sapporo, Hokkaido, 060-8648, Japan
Study Coordinator, Kontakt, +81117161161
Offene Rekrutierung
Hyōgo
Kobe University Hospital ( Site 0914), Kobe, Hyōgo, 650-0017, Japan
Study Coordinator, Kontakt, +81783825111
Offene Rekrutierung
Ishikawa-ken
Kanazawa Medical University Hospital ( Site 0909), Mukai-awagasaki, Ishikawa-ken, 920-0265, Japan
Study Coordinator, Kontakt, +81-76-286-3511
Offene Rekrutierung
Kagawa-ken
Kagawa University Hospital ( Site 0917), Kita, Kagawa-ken, 761-0701, Japan
Study Coordinator, Kontakt, +81878985111
Offene Rekrutierung
Kanagawa
Yokohama City University Medical Center ( Site 0908), Yokohama, Kanagawa, 232-0024, Japan
Study Coordinator, Kontakt, +81452615656
Offene Rekrutierung
Nagasaki
National Hospital Organization Nagasaki Medical Center ( Site 0923), Ōmura, Nagasaki, 856-8562, Japan
Study Coordinator, Kontakt, +81-957-52-3121
Offene Rekrutierung
Nara
Nara Medical University Hospital ( Site 0915), Kashihara, Nara, 634-8522, Japan
Aktiv, nicht rekrutierend
Okinawa
Nanbu Tokushukai Hospital ( Site 0930), Shimajiri, Okinawa, 901-0417, Japan
Study Coordinator, Kontakt, +81-98-998-3221
Offene Rekrutierung
Osaka
Kansai Medical University Hospital ( Site 0912), Hirakata, Osaka, 573-1191, Japan
Study Coordinator, Kontakt, +81-72-804-0101
Offene Rekrutierung
Bell Land General Hospital ( Site 0913), Sakai, Osaka, 599-8247, Japan
Study Coordinator, Kontakt, +81722342001
Offene Rekrutierung
The University of Osaka Hospital ( Site 0911), Suita, Osaka, 565-0871, Japan
Study Coordinator, Kontakt, +81668795111
Offene Rekrutierung
Saga-ken
Saga-Ken Medical Centre Koseikan ( Site 0922), Saga, Saga-ken, 840-8571, Japan
Aktiv, nicht rekrutierend
Tokyo
The Jikei University Hospital ( Site 0907), Minato, Tokyo, 105-8471, Japan
Aktiv, nicht rekrutierend
Akita University Hospital ( Site 0904), Akita, 010-8543, Japan
Study Coordinator, Kontakt, +81188341111
Offene Rekrutierung
Kyushu University Hospital ( Site 0919), Fukuoka, 812-8582, Japan
Study Coordinator, Kontakt, +81926411151
Offene Rekrutierung
Fukushima Medical University Hospital ( Site 0933), Fukushima, 960-1295, Japan
Study Coordinator, Kontakt, +81245471111
Offene Rekrutierung
Gifu University Hospital ( Site 0910), Gifu, 501-1112, Japan
Study Coordinator, Kontakt, +81-58-230-6000
Offene Rekrutierung
Hiroshima University Hospital ( Site 0916), Hiroshima, 734-8551, Japan
Study Coordinator, Kontakt, +81-82-257-5555
Offene Rekrutierung
Kagoshima University Hospital ( Site 0929), Kagoshima, 890-8520, Japan
Study Coordinator, Kontakt, +81-99-275-5111
Offene Rekrutierung
National Hospital Organization Kumamoto Medical Center ( Site 0924), Kumamoto, 860-0008, Japan
Study Coordinator, Kontakt, +81963536501
Offene Rekrutierung
Miyazaki Prefectural Miyazaki Hospital ( Site 0927), Miyazaki, 880-8510, Japan
Study Coordinator, Kontakt, +81985244181
Offene Rekrutierung
University of Miyazaki Hospital ( Site 0926), Miyazaki, 889-1692, Japan
Study Coordinator, Kontakt, +81-98-585-1510
Offene Rekrutierung
Nagano Municipal Hospital ( Site 0932), Nagano, 381-8551, Japan
Study Coordinator, Kontakt, +81-26-295-1199
Offene Rekrutierung
National Hospital Organization Oita Medical Center ( Site 0925), Ōita, 870-0263, Japan
Aktiv, nicht rekrutierend
Johor
Hospital Sultan Ismail ( Site 1081), Johor Bahru, Johor, 81100, Malaysia
Study Coordinator, Kontakt, +6073565155
Offene Rekrutierung
Kuala Lumpur
University Malaya Medical Centre ( Site 1077), Lembah Pantai, Kuala Lumpur, 59100, Malaysia
Aktiv, nicht rekrutierend
Putrajaya
National Cancer Institute ( Site 1079), Putrajaya, Putrajaya, 62250, Malaysia
Study Coordinator, Kontakt, +60388925418
Offene Rekrutierung
Sarawak
Sarawak General Hospital-Radiotherapy Unit ( Site 1076), Kuching, Sarawak, 93586, Malaysia
Study Coordinator, Kontakt, +6082276820
Offene Rekrutierung
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078), Kuala Lumpur, 50586, Malaysia
Study Coordinator, Kontakt, +60326155810
Offene Rekrutierung
Jalisco
CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103), Guadalajara, Jalisco, 44630, Mexico
Aktiv, nicht rekrutierend
Mexico City
Quemex Medical and Research ( Site 1112), Mexico City, Mexico City, 14308, Mexico
Aktiv, nicht rekrutierend
Nuevo León
Filios Alta Medicina ( Site 1106), Monterrey, Nuevo León, 64460, Mexico
Aktiv, nicht rekrutierend
Yucatán
Medical Care and Research SA de CV ( Site 1108), Mérida, Yucatán, 97070, Mexico
Aktiv, nicht rekrutierend
Centro de Investigacion Clinica de Oaxaca ( Site 1109), Oaxaca City, 68020, Mexico
Aktiv, nicht rekrutierend
Gelderland
Radboudumc-Medical Oncology ( Site 1152), Nijmegen, Gelderland, 6525 GA, Netherlands
Study Coordinator, Kontakt, +31 (0)24 361 0353
Offene Rekrutierung
Limburg
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163), Sittard-Geleen, Limburg, 6162 BG, Netherlands
Aktiv, nicht rekrutierend
VieCuri Medisch Centrum ( Site 1173), Venlo, Limburg, 5912 BL, Netherlands
Aktiv, nicht rekrutierend
North Brabant
ETZ Elisabeth-Internal Medicine ( Site 1160), Tilburg, North Brabant, 5022 GC, Netherlands
Study Coordinator, Kontakt, +3113221 0210
Offene Rekrutierung
North Holland
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153), Amsterdam, North Holland, 1066 CX, Netherlands
Study Coordinator, Kontakt, +31205122569
Offene Rekrutierung
Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, North Holland, 1081 HV, Netherlands
Aktiv, nicht rekrutierend
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170), Hoofddorp, North Holland, 2134 TM, Netherlands
Study Coordinator, Kontakt, +31232245802
Offene Rekrutierung
Provincie Friesland
Medische Centrum Leeuwarden ( Site 1172), Leeuwarden, Provincie Friesland, 8934 AD, Netherlands
Study Coordinator, Kontakt, +31582866660
Offene Rekrutierung
South Holland
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151), Schiedam, South Holland, 3118 JH, Netherlands
Study Coordinator, Kontakt, 003110- 4617590
Offene Rekrutierung
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164), The Hague, South Holland, 2545 AA, Netherlands
Study Coordinator, Kontakt, +31702102143
Offene Rekrutierung
Utrecht
Meander Medisch Centrum ( Site 1157), Amersfoort, Utrecht, 3813TZ, Netherlands
Study Coordinator, Kontakt, +003133 - 850 1189
Offene Rekrutierung
Bay of Plenty
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201), Tauranga, Bay of Plenty, 3112, New Zealand
Study Coordinator, Kontakt, +64277033845
Offene Rekrutierung
Otago
Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203), Dunedin, Otago, 9016, New Zealand
Study Coordinator, Kontakt, +64 3 470 9692
Offene Rekrutierung
Akershus
Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227), Lørenskog, Akershus, 1474, Norway
Study Coordinator, Kontakt, +4767963800
Offene Rekrutierung
Sor-Trondelag
St. Olavs Hospital-Kreftklinikken ( Site 1231), Trondheim, Sor-Trondelag, 7030, Norway
Aktiv, nicht rekrutierend
Østfold fylke
Sykehuset Østfold Kalnes ( Site 1228), Sarpsborg, Østfold fylke, 1714, Norway
Aktiv, nicht rekrutierend
Departamento de Junín
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258), Concepción, Departamento de Junín, 12125, Peru
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
La Libertad
Clínica Sánchez Ferrer ( Site 1261), Trujillo, La Libertad, 13009, Peru
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Aliada-Oncologìa ( Site 1257), Lima, 15036, Peru
Aktiv, nicht rekrutierend
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254), Lima, 15036, Peru
Aktiv, nicht rekrutierend
Oncosalud-Clinical Research ( Site 1260), Lima, 15036, Peru
Aktiv, nicht rekrutierend
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256), Lima, 15038, Peru
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Kuyavian-Pomeranian Voivodeship
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1302), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Study Coordinator, Kontakt, +48523743589
Offene Rekrutierung
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316), Grudziądz, Kuyavian-Pomeranian Voivodeship, 86-300, Poland
Study Coordinator, Kontakt, +48566414444
Offene Rekrutierung
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304), Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
Aktiv, nicht rekrutierend
Masovian Voivodeship
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310), Siedlce, Masovian Voivodeship, 08-110, Poland
Study Coordinator, Kontakt, +48256403301
Offene Rekrutierung
West Pomeranian Voivodeship
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303), Koszalin, West Pomeranian Voivodeship, 75-581, Poland
Study Coordinator, Kontakt, +48943488930
Offene Rekrutierung
Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, West Pomeranian Voivodeship, 71-730, Poland
Study Coordinator, Kontakt, +48914251502
Offene Rekrutierung
Świętokrzyskie Voivodeship
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318), Kielce, Świętokrzyskie Voivodeship, 25-734, Poland
Study Coordinator, Kontakt, +48413674811
Offene Rekrutierung
Puerto Rico Medical Research Center LLC ( Site 1354), Hato Rey, 00917, Puerto Rico
Aktiv, nicht rekrutierend
Ad-Vance Medical Research-Research ( Site 1353), Ponce, 00717, Puerto Rico
Study Coordinator, Kontakt, 787-651-6697
Offene Rekrutierung
Pan American Center for Oncology Trials - Ciudadela ( Site 1351), San Juan, 00909, Puerto Rico
Aktiv, nicht rekrutierend
Central Singapore
National University Hospital ( Site 1376), Singapore, Central Singapore, 119074, Singapore
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
National Cancer Centre Singapore ( Site 1377), Singapore, Central Singapore, 168583, Singapore
Study Coordinator, Kontakt, +65-64368000
Offene Rekrutierung
Tan Tock Seng Hospital-Medical Oncology ( Site 1378), Singapore, Central Singapore, 308433, Singapore
Study Coordinator, Kontakt, +65-62566011
Offene Rekrutierung
Seoul
Asan Medical Center-Oncology ( Site 1402), Songpagu, Seoul, 05505, South Korea
Aktiv, nicht rekrutierend
Seoul National University Hospital-Oncology ( Site 1401), Seoul, 03080, South Korea
Study Coordinator, Kontakt, +82220721672
Offene Rekrutierung
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404), Seoul, 03722, South Korea
Study Coordinator, Kontakt, +82222288138
Offene Rekrutierung
Samsung Medical Center ( Site 1405), Seoul, 06351, South Korea
Study Coordinator, Kontakt, +82234101767
Offene Rekrutierung
Cadiz
Hospital Jerez de la Frontera ( Site 1427), Jerez de la Frontera, Cadiz, 11407, Spain
Study Coordinator, Kontakt, +34661753582
Offene Rekrutierung
Madrid, Comunidad de
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431), Madrid, Madrid, Comunidad de, 28034, Spain
Study Coordinator, Kontakt, 34913368263
Offene Rekrutierung
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433), Madrid, Madrid, Comunidad de, 28041, Spain
Study Coordinator, Kontakt, 608464547
Offene Rekrutierung
Orense
Complexo Hospitalario Universitario de Ourense ( Site 1426), Ourense, Orense, 32005, Spain
Study Coordinator, Kontakt, +34988385471
Offene Rekrutierung
Valenciana, Comunitat
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430), Valencia, Valenciana, Comunitat, 46009, Spain
Study Coordinator, Kontakt, +34 961114229
Offene Rekrutierung
Hospital Lucus Augusti-Oncology ( Site 1432), Lugo, 27003, Spain
Study Coordinator, Kontakt, +34982296459
Offene Rekrutierung
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428), Seville, 41013, Spain
Study Coordinator, Kontakt, 34955013068
Offene Rekrutierung
Stockholm County
Karolinska Universitetssjukhuset Solna ( Site 1478), Stockholm, Stockholm County, 171 64, Sweden
Aktiv, nicht rekrutierend
Uppsala County
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477), Uppsala, Uppsala County, 751 85, Sweden
Study Coordinator, Kontakt, 0046186110000
Offene Rekrutierung
Västra Götaland County
Sahlgrenska Universitetssjukhuset ( Site 1479), Gothenburg, Västra Götaland County, 413 45, Sweden
Study Coordinator, Kontakt, 0046313421000
Offene Rekrutierung
China Medical University Hospital-Department of Urology ( Site 1503), Taichung, 40447, Taiwan
Study Coordinator, Kontakt, +886-4-2205-2121
Offene Rekrutierung
National Cheng Kung University Hospital-Urology ( Site 1502), Tainan, 704, Taiwan
Study Coordinator, Kontakt, +886-6-2353535
Offene Rekrutierung
National Taiwan University Hospital-Urology ( Site 1506), Taipei, 10002, Taiwan
Aktiv, nicht rekrutierend
Taipei Veterans General Hospital ( Site 1505), Taipei, 112, Taiwan
Study Coordinator, Kontakt, +886-2-28712121
Offene Rekrutierung
Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504), Taoyuan District, 333, Taiwan
Study Coordinator, Kontakt, +886-3-3281200
Offene Rekrutierung
Bangkok
Chulalongkorn University ( Site 1530), Bangkok, Bangkok, 10330, Thailand
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Faculty of Medicine Siriraj Hospital ( Site 1531), Bangkok, Bangkok, 10700, Thailand
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Changwat Khon Kaen
Faculty of Medicine - Khon Kaen University ( Site 1526), Muang, Changwat Khon Kaen, 40002, Thailand
Study Coordinator, Kontakt, +66 43 366568-9
Offene Rekrutierung
Changwat Songkhla
Songklanagarind hospital ( Site 1527), Hat Yai, Changwat Songkhla, 90110, Thailand
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554), Adana, 01250, Turkey (Türkiye)
Study Coordinator, Kontakt, +903223444444
Offene Rekrutierung
Gulhane Egitim Arastirma Hastanesi ( Site 1558), Ankara, 06010, Turkey (Türkiye)
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551), Ankara, 06230, Turkey (Türkiye)
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Memorial Ankara Hastanesi-Medical Oncology ( Site 1557), Ankara, 06520, Turkey (Türkiye)
Study Coordinator, Kontakt, 903122536666
Offene Rekrutierung
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552), Ankara, 06800, Turkey (Türkiye)
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555), Istanbul, 34668, Turkey (Türkiye)
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553), Istanbul, 34722, Turkey (Türkiye)
Study Coordinator, Kontakt, +902166065200
Offene Rekrutierung
Samsun Medical Park Hastanesi-medical oncology (1560), Samsun, 55200, Turkey (Türkiye)
Dilek Erdem, Kontakt, 905364247616, [email protected]
Offene Rekrutierung
Cambridgeshire
Addenbrooke's Hospital ( Site 1605), Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom
Study Coordinator, Kontakt, 01223216083
Offene Rekrutierung
England
The Royal Cornwall Hospital ( Site 1610), Truro, England, TR1 3LJ, United Kingdom
Study Coordinator, Kontakt, 01872258345
Offene Rekrutierung
Glasgow City
The Beatson West of Scotland Cancer Centre ( Site 1603), Glasgow, Glasgow City, G12 0YN, United Kingdom
Study Coordinator, Kontakt, 1-888-577-8839
Offene Rekrutierung
Hammersmith and Fulham
Charing Cross Hospital-Oncology Research ( Site 1606), London, Hammersmith and Fulham, W6 8RF, United Kingdom
Study Coordinator, Kontakt, 0208 331 10277
Offene Rekrutierung
London, City of
University College London Hospital ( Site 1612), London, London, City of, NW1 2PG, United Kingdom
Aktiv, nicht rekrutierend
The Christie NHS Foundation Trust ( Site 1608), Manchester, m20 4bx, United Kingdom
Study Coordinator, Kontakt, +441614463000
Offene Rekrutierung